About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...